Resmetirom for fatty liver disease with heart failure
Treatments studied
Part of Digestive system, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests a drug called resmetirom for people who have both a type of fatty liver disease (MASH) and a type of heart failure (HFpEF). It aims to see if the drug can help both conditions. You may be able to join if you have both conditions and meet certain health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to have fatty liver disease with scarring (MASH), or it must be strongly suspected.
- You need a confirmed diagnosis of heart failure with preserved pumping function (HFpEF).
- Your kidneys must be working well enough (confirmed by a blood test).
- Women who can get pregnant must use reliable birth control and not be breastfeeding.
- You cannot have cirrhosis or other serious liver conditions.
- You must not have a history of heavy alcohol use or significant alcohol-related problems.
- Your blood sugar control (if diabetic) must be stable enough (HbA1c under 9%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, resmetirom, to see if it can help people who have had a liver transplant for MASH and now have fatty buildup in their new liver. It may also help people who had a transplant for other reasons but developed fatty liver afterward. The study focuses on those with moderate to advanced liver scarring (F2-F3).
This trial tests if resmetirom can help people with MASH, a type of fatty liver disease linked to metabolic issues like diabetes or obesity. It looks at how safe and effective the drug is over time.
This study tests a daily pill, resmetirom, to see if it can reduce fat and scarring in the livers of children and teens with MASH, a type of fatty liver disease. It may help improve liver health and prevent further damage.
This study tests whether taking rezdiffra (a liver medication) together with other common diabetes or liver drugs is safe and effective for adults with MASH (fatty liver disease) and moderate-to-severe liver scarring. It may help improve liver health and reduce disease progression.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This study tests whether adding a special diet plan to the medication resmetirom helps people with a type of fatty liver disease called MASH. If you have this liver condition (without cirrhosis) and are already starting resmetirom, the diet may improve your liver health and overall well-being.
Hear when a new MASH - Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.